Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

Share

May 2018; 5 (3) ArticleOpen Access

Rituximab before and during pregnancy

A systematic review, and a case series in MS and NMOSD

Gitanjali Das, Vincent Damotte, Jeffrey M. Gelfand, Carolyn Bevan, Bruce A.C. Cree, Lynn Do, Ari J. Green, Stephen L. Hauser, Riley Bove
First published March 19, 2018, DOI: https://doi.org/10.1212/NXI.0000000000000453
Gitanjali Das
From the Department of Neurology, Weill Institute for the Neurosciences, University of California, San Francisco.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent Damotte
From the Department of Neurology, Weill Institute for the Neurosciences, University of California, San Francisco.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey M. Gelfand
From the Department of Neurology, Weill Institute for the Neurosciences, University of California, San Francisco.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolyn Bevan
From the Department of Neurology, Weill Institute for the Neurosciences, University of California, San Francisco.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruce A.C. Cree
From the Department of Neurology, Weill Institute for the Neurosciences, University of California, San Francisco.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lynn Do
From the Department of Neurology, Weill Institute for the Neurosciences, University of California, San Francisco.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ari J. Green
From the Department of Neurology, Weill Institute for the Neurosciences, University of California, San Francisco.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen L. Hauser
From the Department of Neurology, Weill Institute for the Neurosciences, University of California, San Francisco.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Riley Bove
From the Department of Neurology, Weill Institute for the Neurosciences, University of California, San Francisco.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Rituximab before and during pregnancy
A systematic review, and a case series in MS and NMOSD
Gitanjali Das, Vincent Damotte, Jeffrey M. Gelfand, Carolyn Bevan, Bruce A.C. Cree, Lynn Do, Ari J. Green, Stephen L. Hauser, Riley Bove
Neurol Neuroimmunol Neuroinflamm May 2018, 5 (3) e453; DOI: 10.1212/NXI.0000000000000453

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
3703

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Objective To evaluate the safety of rituximab treatment before and during pregnancy in women with MS and neuromyelitis optica spectrum disorders (NMOSDs) who may be at risk of relapses by performing a systematic literature review combined with a retrospective single-center case series.

Methods Studies were systematically identified in the PubMed, Google Scholar, and EMBASE using the key terms “pregnancy” and “rituximab”; 22 articles were included for review (>17,000 screened). Then, patients with MS and NMOSD from 1 center (University of California, San Francisco) exposed to rituximab before conception were identified through medical record review.

Results Systematic review: We identified 102 pregnancies with rituximab use within 6 months of conception: 78 resulted in live births and 12 in spontaneous abortions. Of 54 live births with reported gestational age, 31 occurred at term (37 weeks+) and 2 before 32 weeks. When checked, B-cell counts were low in 39% of newborns and normalized within 6 months. Case series: we identified 11 pregnancies (1 ongoing) in 10 women (7 MS and 3 NMOSD) treated with rituximab within 6 months of conception. All completed pregnancies resulted in term live births of healthy newborns (1 lost to follow-up at term). No maternal relapses occurred before/during pregnancy; 1 occurred postpartum (NMOSD).

Conclusion No major safety signal was observed with rituximab use within 6 months of conception. Beyond the need for monitoring neonatal B cells, these observations support prospectively monitoring a larger patient cohort to determine whether rituximab may safely protect women with MS and NMOSD who are planning a pregnancy against relapses.

Glossary

DMT=
disease-modifying therapy;
NMOSD=
neuromyelitis optica spectrum disorder

Women are disproportionately affected by MS and neuromyelitis optica spectrum disorders (NMOSDs), and management of disease-modifying therapies (DMTs) before pregnancy represents an ongoing challenge for neurologists. No safety concerns have been identified with platform injectable DMTs,1,–,3 but discontinuation before pregnancy is typically recommended for the more potent oral and infusible DMTs. Therefore, many women may face a heightened risk of relapses during the period between DMT discontinuation and the potentially protective (in MS4,5 but not in NMOSD6,7) effects of pregnancy. This risk could be further magnified by recurrence of severe “rebound” MS disease activity after discontinuing natalizumab8,–,12 or fingolimod,13,–,16 and in fact these two DMTs appear associated with a higher risk of relapse during pregnancy in the new treatment era.

Rituximab, frequently used off-label for the treatment of MS and NMOSD,17,18 may offer distinct advantages for managing women at the time of conception. First, its biological effects (B-cell depletion) persist long after the drug is effectively eliminated (typically, 5 maximal half-lives3 each of 19–22 days or approximately 110 days19). These data suggest that women could attempt conception approximately 3.5 months after their last infusion without significant risk of fetal exposure to the monoclonal antibody, while conferring protection against MS flares throughout the pregnancy. In addition, should a woman unintentionally conceive before rituximab elimination, the risk of fetal exposure is low, as IgG1 subclass antibodies are not transferred across the placenta during the first trimester. Finally, transition to rituximab from natalizumab may confer protection against the risk of a rebound of disease activity associated with natalizumab withdrawal.20

To date, pregnancy and neonatal outcomes in women with MS and NMOSD treated with rituximab are largely unreported.3,20 To bridge this gap, we performed a systematic review of the medical literature, combined with a retrospective single-center case series.

Methods

Systematic review

To summarize and analyze the existing literature on pregnancy outcomes in women treated with rituximab for any indication within 6 months of conception through delivery, we performed a systematic review.

Data sources

Original research studies were identified from the PubMed/MEDLINE, EMBASE, and Google Scholar databases. The search terms “pregnancy” and “rituximab” were used in combination to include all articles with the key words for all years (last updated July 3, 2017). Further hand searching of reference lists of obtained articles was performed.

Study selection

This search yielded over 17,000 results; titles and abstracts were screened for relevance, and relevant manuscripts underwent subsequent review. Studies were excluded if they were not written in English, were reviews with no specific individual- or cohort-level data, or if mothers were exposed to rituximab more than 6 months before conception (list of citations available upon request). Twenty-two publications were included in the current review, with 102 mothers exposed to rituximab in the desired timeline (see Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram,21 figure).

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for systematic review

Data extraction and analysis

Data were extracted (G.D.) and checked (R.B.) for individual-level information relating to maternal and fetal outcomes. Most articles were case reports, a few were retrospective, and 1 was a meta-analysis of a database; none included control groups.

Retrospective single-center case series

Sample selection

To identify a cohort of women with MS or NMOSD treated with rituximab within 6 months of conception or during delivery at the University of California, San Francisco (UCSF) Multiple Sclerosis and Neuroinflammation Center, we performed search of relevant medical records. Among 323 patients with CNS inflammatory disorders who treated with rituximab between August 2010 and July 2017, we identified 160 women who received rituximab infusions before the age of 50 years. Their medical records were manually reviewed to identify pregnancies occurring within 6 months of exposure to rituximab. We identified 10 women with at least 1 pregnancy occurring within the selected timeframe. These were cross-referenced with participating clinicians' individual caseloads.

Data collection

Medical records were reviewed to record pregnancy outcomes (delivery or fetal loss), maternal MS or NMOSD disease activity during pregnancy and postpartum (relapses, symptoms, and medications), maternal pregnancy-related and other complications (e.g., preeclampsia), and neonatal outcomes (gestational age, delivery mode, and newborn health status).

Standard protocol approvals, registrations, and patient consents

The UCSF Committee of Human Research approved the study protocol for retrospective analysis of electronic medical record–derived MS data with no patient contact (Ref #13-11686).

Results

Systematic review

We identified 102 women who became pregnant within 6 months of exposure to rituximab or who were treated with rituximab while pregnant. Of these 102 patients, 38 were described in case reports or small case series, and 64 were described in a meta-analysis22 (table 1). Medical indications for rituximab treatment included 2 cases with NMOSD, as well as lymphoma, rheumatoid arthritis, and immune-mediated thrombocytopenic purpura, among others. Many mothers experienced successful medical management for their primary condition with rituximab.

View this table:
  • View inline
  • View popup
Table 1

Systematic review of 22 articles reporting maternal and fetal outcomes for 102 pregnancies characterized by maternal treatment with rituximab within 6 months of conception or during pregnancy

A total of 74 of the 102 pregnancies reported resulted in live births. In the 41 pregnancies from the case reports and case series, 1 fetal demise was reported at 21 weeks of gestation in a patient with a history of miscarriages23 and 1 stillbirth was reported at 27 weeks of gestation due to placental insufficiency.24 There was also 1 therapeutic abortion and 1 spontaneous abortion in a patient taking methotrexate until confirmation of pregnancy.24 In the larger meta-analysis of the global drug safety database investigating fetal outcomes in patients with rituximab exposure (64 pregnancies with 1 ongoing at the time of publication), 11 spontaneous abortions were reported, as well as 15 medical abortions.22 These mothers were often taking other medications, including methotrexate, an antifolate drug that is often used to treat ectopic pregnancies.

Newborns were delivered at term (37 weeks of gestational age or after) in 31 of the 54 live births, where gestational age was reported. None of the deliveries were severely preterm (less than 28 weeks of gestation, according to the World Health Organization guidelines), and 2 were born before 32 weeks. One mother on an rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone regimen for lymphoma underwent emergency cesarean section at 34 weeks due to fetal distress. The baby was born with a patent ductus arteriosus that was fixed the day after birth.25 Besides, the patent ductus arteriosus, the only other newborn physical abnormalities or medical conditions reported involved twins: one was born with a clubfoot and the other with erythema toxicum neonatorum. Both twins developed normally and did not have any complications.26

Neonatal B-cell depletion was found in 9 of the 23 pregnancies in which B-cell counts were measured and reported. None of these neonates experienced any infectious complications, and none were noted to experience any adverse reactions to vaccinations. All B-cell levels normalized within 6 months, some sooner.

Retrospective single-center case series

We identified a total of 11 pregnancies from 10 patients who became pregnant within 6 months of rituximab exposure (table 2): 6 with MS and 3 with NMOSD, with pregnancy ongoing in 1 patient at the time of data collection. No patients received rituximab infusions while pregnant. No patients experienced relapses between rituximab treatment and conception.

View this table:
  • View inline
  • View popup
Table 2

Pregnancy and neonatal characteristics in 11 pregnancies characterized by maternal exposure to rituximab for treatment of demyelinating diseases within 6 months of conception: a single-center case series

Medical complications arose in 4 of the 10 completed pregnancies and included pregnancy-related (gestational diabetes, pre-eclampsia with postpartum eclampsia) and disease-related (blurring of vision and lightheadedness at about 5 months of gestation and worsening spasticity; numbness in fingertips 2 weeks before delivery); neither of the disease-related complications was determined by the treating neurologist to represent a clinical relapse, and neither required additional medications or hospitalizations.

Of the 10 completed pregnancies, 9 resulted in term live births, with healthy children (status unknown for 1 as the mother moved out of the area and closer to familial supports for delivery). Most mothers breastfed for at least a few weeks before restarting treatment. One patient of the 8 with data for the full-year postpartum, who carried an NMOSD diagnosis, relapsed postpartum.

Discussion

Rituximab, which seems to reduce relapse frequency in both MS and NMOSD, may offer significant advantages for women with MS and NMOSD who are planning a pregnancy and require ongoing DMT, given that its biological effect extends significantly beyond its pharmacokinetic half-life. Although individual variability exists in terms of the exact half-life of rituximab,27 or of any administered monoclonal antibody, an estimate of effective elimination would require 5 maximal half-lives3 each of 19–22 days or approximately 110 days.19 B-cell repletion occurs in most individuals within 8 months, but in the phase 2 study of rituximab, MS disease activity remained suppressed 1 year after a single course of treatment. However, not enough is known about pregnancy outcomes in women with MS and NMOSD who conceive after rituximab treatment to fully understand the risks and advantages of this approach.

In the current systematic review of pregnancy outcomes in women with a number of medical conditions treated with rituximab (some with severe diseases and using other concomitant medications), we calculated an overall reported rate of spontaneous abortions of 12%, and 41% of reported deliveries occurred before 37 weeks (2 before 32 weeks). Three malformations or medical conditions were reported among the 67 newborns (as a point of reference from the general population in the United States, the rate of major malformations at birth is 3%28). The primary adverse effect noted was a low neonatal B-cell count in 39% of the newborns evaluated that normalized within 6 months in all cases. Of interest, in 1 patient with NMOSD whose last treatment with 100 mg rituximab was 7 months before conception, a low B-cell percentage detected in fetal cord blood suggested that maternal rituximab treatment might influence fetal B-cell counts even after rituximab should have been completely eliminated from the maternal circulation.21

Limitations of this literature review include the retrospective nature and small size of the cases series and reports, potential under-reporting, and lack on information on potential confounders. For example, the coexisting use of glucocorticoids, antimetabolites, and other chemotherapy agents could potentially confound any causal role attributed to rituximab for these adverse events. Furthermore, there was little information on other possible confounding variables such as obstetrical or clinical disease histories, which could also influence the pregnancy course and outcome. Prospective evaluation of pregnancy outcomes, including case-control studies evaluating the rates of pregnancy loss or prematurity, as well as longer term information about children's immunologic trajectories, is required to overcome the current limitations and biases. Nonetheless, this review did not identify major concerns that would preclude treatment with rituximab within 6 months of conception in women with demyelinating diseases at risk of inflammatory activity when discontinuing other MS medications before conception.

Next, in our preliminary case series of 11 pregnancies in women with demyelinating diseases treated with rituximab within 6 months of conception, none of the patients experienced a relapse before conception or during pregnancy. Those with completed pregnancies did not experience major rebound activity after delivery; only 1 patient (NMOSD) experienced a postpartum relapse (up to 1/3 women with MS have been reported to relapse postpartum). Most of the treated patients breastfed for at least a few weeks before receiving another dose of rituximab. All children were reported to be healthy at birth and to remain healthy at follow-up.

Limitations from the current case series include the small sample size and possible bias if some pregnancies in women not receiving primary or obstetrical care in the same hospital system as our tertiary care center were not captured in the patient's medical record. However, given the complex medical decision making that typically happens at the time of conception and delivery in women with demyelinating diseases, it is likely that we identified most of the pregnancies within our rituximab-treated cohort. Furthermore, to date, regular B-cell monitoring in the mother during and after pregnancy and in the neonate has not been routinely performed in our clinic. As decreased neonatal B-cell counts were noted in the systematic review, this information would provide additional insights into the effect of rituximab intrapartum and postpartum and would allow optimization of the timing of rituximab treatment. Finally, there were no patients in our single-center case series who received rituximab during pregnancy, limiting discussion of possible effects of intrapartum maternal treatment and fetal exposure.

Currently, to treat women with demyelinating diseases during pregnancy, glatiramer acetate can be used before, and even during, pregnancy; but some therapies commonly used in MS are relatively contraindicated.29 Fingolimod, dimethyl fumarate, and teriflunomide are small molecules that could cross the placenta and potentially cause birth defects. Natalizumab treatment during pregnancy may be associated with neonatal pancytopenia,30 and natalizumab treatment discontinuation can be associated with recurrence of severe MS disease activity.31 For example, in a retrospective study evaluating 22 pregnancies after discontinuation of natalizumab, recurrence of disease activity was noted in 95.5% of the cases, despite little to no activity in the year before natalizumab discontinuation.32 Disease activity seemed more limited when conception occurred shortly after or even before discontinuation of natalizumab, with recurrence of disease activity often occurring 4–6 months after discontinuation. To our knowledge, no data on daclizumab use during pregnancy are available in humans. Like rituximab, alemtuzumab has a pharmacodynamic effect that is far longer than its pharmacokinetic half-life and theoretically could be used in women with MS who are planning pregnancy. However, alemtuzumab-treated patients are at high risk for treatment-related, de novo thyroid and other autoimmune diseases. Because maternal autoantibodies can be transmitted across the placental barrier and thereby can cause disease in the fetus or newborn, treatment with alemtuzumab before pregnancy must be approached with caution. In March 2017, ocrelizumab, a humanized monoclonal anti-CD20 antibody, was approved by the US Food and Drug Administration for both relapsing and progressive MS.33 Its average half-life is 26 days—possibly shortening the preconception therapeutic window relative to rituximab. In an initial report of 9 women whose embryo/fetus was considered “exposed” to ocrelizumab (i.e., here, infusion within 3 months of conception) during the MS clinical trials, pregnancy outcomes included 1 healthy term baby, 6 elective terminations, and 2 ongoing pregnancies.34 Therefore, an unmet need for effective treatments for women living with MS and NMOSD who are considering pregnancy remains.

While awaiting prospective pregnancy and postpartum monitoring, the current systematic review and case series provide some preliminary reassurance that rituximab may offer a window of time before conception during which inflammatory activity can be mitigated, without evidence of major adverse effects during pregnancy. Longer term follow-up and a larger sample size are needed to determine the safety of rituximab before and during pregnancy in women with MS and NMOSD, and independent studies will be required to assess the potential benefits and risks of other B-cell depleting agents such as ocrelizumab in this situation.

Author contributions

Study concept and design: G.D., J.M.G., B.A.C.C., and R.B. Statistical analysis and interpretation of data: G.D. and R.B. Acquisition of data and interpretation of results: G.D., V.D., L.D., and R.B. Manuscript drafting and revision: G.D., V.D., J.M.G., C.B., B.A.C.C., L.D., A.G., S.H., and R.B.

Study funding

This research was supported by the National Multiple Sclerosis Society Career Transition Award (R.B.).

Disclosure

G. Das reports no disclosures. V. Damotte received a travel grant from the ECTRIMS and research support from the ARSEP Foundation. J.M. Gelfand served on the scientific advisory board of Genentech; received research support to UCSF from Genentech; his spouse served on a scientific advisory board of Eli Lilly; is viewpoints editor of JAMA Neurology; consulted for Zosano, Biohaven, and Eli Lilly; and received research support to UCSF from eNeura and Allergan. C. Bevan reports no disclosures. B.A.C. Cree served as an editor of Annals of Neurology; consulted for AbbVie, Biogen, EMD Serono, GeNeuro, Novartis, and Sanofi-Genzyme; and received research support from Acorda, Celgene, Hoffman-LaRoche, MedImmune, Novartis, and Teva. L. Do reports no disclosures. A. Green served on the scientific advisory board of MedImmune, Novartis, Inception 5 Biosciences, and Bionure; served on the editorial board of JAMA Neurology and Neurology; holds a patent for Remyelination molecules and pathways; consulted for Inception 5 Sciences; received research support from Novartis Pharma OCTIMS, Inception Sciences, the NINDS, the NIA, the National MS Society, the Sherak Foundation, and the Hilton Foundation; and served as an expert witness of Mylan Pharma vs Teva Pharma. S. Hauser served on the scientific advisory board of Symbiotix, Annexon, Bionure, and Molecular Stethoscope; serves on the board of trustees of Neurona; received travel funding and speaker honoraria from F. Hoffman La Roche; receives publishing royalties from the McGraw-Hill Education, provided writing support for F. Hoffman La Roche; received research support from the NIH, National MS Society, and Conrad N. Hilton Foundation. R. Bove served on the scientific advisory board of Roche-Genentech, Sanofi-Genzyme, and Novartis; received gifts from the Sherak Foundation and Akili; has a patent pending for Selective estrogen receptor modulators and remyelination; and received research support from the California Initiative to Advance Precision Medicine, National MS Society, and Hilton Foundation. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NN.

Footnotes

  • Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NN.

  • The Article Processing Charge was funded by the authors.

  • Received November 29, 2017.
  • Accepted in final form February 9, 2018.
  • Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Herbstritt S,
    2. Langer-Gould A,
    3. Rockhoff M, et al
    . Glatiramer acetate during early pregnancy: a prospective cohort study. Mult Scler J 2016;22:810–816.
    OpenUrl
  2. 2.↵
    1. Thiel S,
    2. Langer-Gould A,
    3. Rockhoff M, et al
    . Interferon-beta exposure during first trimester is safe in women with multiple sclerosis—a prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Mult Scler J 2016;22:801–809.
    OpenUrl
  3. 3.↵
    1. Bove R,
    2. Alwan S,
    3. Friedman JM, et al
    . Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review. Obstet Gynecol 2014;124:1157–1168.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Confavreux C,
    2. Hutchinson M,
    3. Hours MM,
    4. Cortinovis-Tourniaire P,
    5. Moreau T
    . Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998;339:285–291.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Hutchinson M
    . Neurology & Psychiatry Editorial Pregnancy in multiple sclerosis. J Neurol Neurosurg Psychiatr 1993;56:1043–1045.
    OpenUrlFREE Full Text
  6. 6.↵
    1. Davoudi V,
    2. Keyhanian K,
    3. Bove RM,
    4. Chitnis T
    . Immunology of neuromyelitis optica during pregnancy. Neurol Neuroimmunol Neuroinflamm 2016;3:e228. doi: 10.1212/NXI.0000000000000228.
    OpenUrl
  7. 7.↵
    1. Fragoso YD,
    2. Adoni T,
    3. Bichuetti DB, et al
    . Neuromyelitis optica and pregnancy. J Neurol 2013;260:2614–2619.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. González-Suarez I,
    2. Rodríguez de Antonio L,
    3. Orviz A, et al
    . Catastrophic outcome of patients with a rebound after natalizumab treatment discontinuation. Brain Behav 2017;7:1–6.
    OpenUrl
  9. 9.↵
    1. Berger JR,
    2. Centonze D,
    3. Comi G, et al
    . Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Ann Neurol 2010;68:409–411.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Martinelli V,
    2. Colombo B,
    3. Dalla Costa G, et al
    . Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning. Mult Scler 2016;22:1506–1508.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Sorensen PS,
    2. Koch-Henriksen N,
    3. Petersen T,
    4. Ravnborg M,
    5. Oturai A,
    6. Sellebjerg F
    . Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol 2014;261:1170–1177.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Miravalle A,
    2. Jensen R,
    3. Kinkel RP
    . Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 2011;68:186–191.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Meinl I,
    2. Havla J,
    3. Hohlfeld R,
    4. Kümpfel T
    . Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis. Mult Scler Epub 2017 Sep 1:1352458517731913.
  14. 14.↵
    1. Sempere AP,
    2. Berenguer-Ruiz L,
    3. Feliu-Rey E
    . Rebound of disease activity during pregnancy after withdrawal of fingolimod. Eur J Neurol 2013;20:e109–e110.
    OpenUrlPubMed
  15. 15.
    1. Novi G,
    2. Ghezzi A,
    3. Pizzorno M, et al
    . Dramatic rebounds of MS during pregnancy following fingolimod withdrawal. Neurol Neuroimmunol Neuroinflamm 2017;4:e377. doi: 10.1212/NXI.0000000000000377.
    OpenUrl
  16. 16.↵
    1. Alroughani R,
    2. Alowayesh MS,
    3. Ahmed SF,
    4. Behbehani R,
    5. Al-Hashel J
    . Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era. Neurology 2018;90:e840–e846.
    OpenUrl
  17. 17.↵
    1. Etemadifar M,
    2. Salari M,
    3. Mirmosayyeb O, et al
    . Efficacy and safety of rituximab in neuromyelitis optica: review of evidence. J Res Med Sci 2017;22:18.
    OpenUrl
  18. 18.↵
    1. Gelfand JM,
    2. Cree BAC,
    3. Hauser SL
    . Ocrelizumab and other CD20+ B-Cell-Depleting therapies in multiple sclerosis. Neurotherapeutics 2017;14:835–841.
    OpenUrl
  19. 19.↵
    1. Breedveld F,
    2. Agarwal S,
    3. Yin M, et al
    . Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-Cell levels do not correlate with clinical response. J Clin Pharmacol 2007;47:1119–1128.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Alping P,
    2. Frisell T,
    3. Novakova L, et al
    . Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol 2016;79:950–958.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Moher D,
    2. Liberati A,
    3. Tetzlaff J,
    4. Altman D
    . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Preferred reporting Items for systematic reviews and meta-analyses. BMJ 2010;8:b2535.
    OpenUrl
  22. 22.↵
    1. Chakravarty EF,
    2. Murray ER,
    3. Kelman A,
    4. Farmer P
    . Pregnancy outcomes after maternal exposure to rituximab. Blood 2011;117:1499–1506.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Abisror N,
    2. Mekinian A,
    3. Brechignac S,
    4. Ruffatti A,
    5. Carbillon L,
    6. Fain O
    . Inefficacy of plasma exchanges associated to rituximab in refractory obstetrical antiphospholipid syndrome. Press Medicale 2015;44:100–102.
    OpenUrl
  24. 24.↵
    1. De Cock D,
    2. Birmingham L,
    3. Watson KD,
    4. Kearsley-Fleet L,
    5. Symmons DP,
    6. Hyrich KL
    . Pregnancy outcomes in women with rheumatoid arthritis ever treated with rituximab. Rheumatology (Oxford) 2017;56:661–663.
    OpenUrl
  25. 25.↵
    1. Lee EJ,
    2. Ahn KH,
    3. Hong SC,
    4. Lee EH,
    5. Park Y,
    6. Kim BS
    . Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy for diffuse large B-cell lymphoma in pregnancy may be associated with preterm birth. Obstet Gynecol Sci 2014;57:526–529.
    OpenUrl
  26. 26.↵
    1. Ton E,
    2. Tekstra J,
    3. Hellmann PM,
    4. Nuver-Zwart IHH,
    5. Bijlsma JWJ
    . Safety of rituximab therapy during twins' pregnancy. Rheumatology 2011;50:806–808.
    OpenUrlPubMed
  27. 27.↵
    1. Lioger B,
    2. Edupuganti SR,
    3. Mulleman D, et al
    . Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. Br J Clin Pharmacol 2017;83:1773–1781.
    OpenUrl
  28. 28.↵
    1. Rynn L,
    2. Cragan J,
    3. Correa A
    . Update on overall prevalence of major birth defects –- Atlanta, Georgia, 1978–2005 (online). 2008. Available at: cdc.gov/mmwr/preview/mmwrhtml/mm5701a2.htm. Accessed July 9, 2017.
  29. 29.↵
    1. Cree BA
    . Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult Scler J 2013;19:835–843.
    OpenUrl
  30. 30.↵
    1. Guilloton L,
    2. Pegat A,
    3. Defrance J,
    4. Quesnel L,
    5. Barral G,
    6. Drouet A
    . Neonatal pancytopenia in a child, born after maternal exposure to natalizumab throughout pregnancy. J Gynecol Obstet Hum Reprod 2017;46:301–302.
    OpenUrl
  31. 31.↵
    1. Rasenack M,
    2. Derfuss T
    . Disease activity return after natalizumab cessation in multiple sclerosis. Expert Rev Neurother 2016;16:587–594.
    OpenUrl
  32. 32.↵
    1. Kleerekooper I,
    2. van Kempen ZLE,
    3. Leurs CE, et al
    . Disease activity following pregnancy-related discontinuation of natalizumab in MS. Neurol Neuroimmunol Neuroinflamm 2018;5:e424. doi: 10.1212/NXI.0000000000000424.
    OpenUrl
  33. 33.↵
    1. Kappos L,
    2. Li D,
    3. Calabresi PA, et al
    . Ocrelizumab in relapsing-remitting multiple sclerosis : a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011;378:1779–1787.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Wray S,
    2. Bader-Wader S,
    3. Buffels R, et al
    . Pregnancy outcomes following ocrelizumab treatment in patients with multiple sclerosis and other autoimmune diseases. Presented at: 2017 Annual Meeting of the Consortium of Multiple Sclerosis Centers; May 24-27, 2017; New Orleans, LA. Available at: https://cmsc.confex.com/cmsc/2017/webprogram/Paper5011.html. Accessed March 13, 2018.
  35. 35.
    1. Azim HA Jr.,
    2. Azim H,
    3. Peccatori FA
    . Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Expert Rev Clin Immunol 2010;6:821–826.
    OpenUrlCrossRefPubMed
  36. 36.
    1. Burnette BL,
    2. Jentoft MA,
    3. Porrata LF,
    4. Boyce TG,
    5. Witzig TE
    . Single-agent rituximab for primary CNS lymphoma during pregnancy as a bridge to definitive management. J Clin Oncol 2014;32:e14–e17.
    OpenUrlFREE Full Text
  37. 37.
    1. Daver N,
    2. Nazha A,
    3. Kantarjian HM,
    4. Haltom R,
    5. Ravandi F
    . Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options. Clin Lymphoma Myeloma Leuk 2013;13:86–89.
    OpenUrlCrossRefPubMed
  38. 38.
    1. Decker M,
    2. Rothermundt C,
    3. Rochlitz C
    . Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. Lancet Oncol 2006;7:693–694.
    OpenUrlCrossRefPubMed
  39. 39.
    1. Kimby E,
    2. Sverrisdottir A,
    3. Elinder G
    . Safety of rituximab therapy during the first trimester of pregnancy: a case history. Eur J Haematol 2004;72:292–295.
    OpenUrlCrossRefPubMed
  40. 40.
    1. Mandal PK,
    2. Dolai TK,
    3. Bagchi B,
    4. Ghosh MK,
    5. Bose S,
    6. Bhattacharyya M
    . B cell suppression in newborn following treatment of pregnant diffuse large B-cell lymphoma patient with rituximab containing regimen. Indian J Pediatr 2014;81:1092–1094.
    OpenUrl
  41. 41.
    1. Perez CA,
    2. Amin J,
    3. Aguina LM,
    4. Cioffi-Lavina M,
    5. Santos ES
    . Primary Mediastinal large B-Cell lymphoma during pregnancy. Case Rep Hematol 2012;2012:197347.
    OpenUrl
  42. 42.
    1. Rey J,
    2. Coso D,
    3. Roger V, et al
    . Rituximab combined with chemotherapy for lymphoma during pregnancy. Leuk Res 2009;33:2008–2009.
    OpenUrl
  43. 43.
    1. Al-Rabadi L,
    2. Ayalon R,
    3. Bonegio RG, et al
    . Pregnancy in a patient with primary Membranous nephropathy and circulating anti-PLA2R antibodies: a case report. Am J Kidney Dis 2016;67:775–778.
    OpenUrl
  44. 44.
    1. Gall B,
    2. Yee A,
    3. Berry B, et al
    . Rituximab for management of refractory pregnancy-associated immune thrombocytopenic purpura. J Obstet Gynaecol Can 2010;32:1167–1171.
    OpenUrlPubMed
  45. 45.
    1. Laliberte KA,
    2. Greene MF,
    3. Niles JL
    . Fetal outcomes after rituximab exposure in women with autoimmune vasculitis. Ann Rheum Dis 2015;72:2051–2053.
    OpenUrl
  46. 46.
    1. Mariampillai AI,
    2. Garrison M,
    3. Zervoudakis AA
    . Rituximab for prevention of recurrent pregnancy related thrombotic thrombocytopenic purpura in high risk patients with previous episodes of thrombotic thrombocytopenic purpura during pregnancy. Blood 2016;128:4940.
    OpenUrl
  47. 47.
    1. Martínez-Martínez MU,
    2. Baranda-Cándido L,
    3. González-Amaro R,
    4. Pérez-Ramírez O,
    5. Abud-Mendoza C
    . Modified neonatal B-cell repertoire as a consequence of rituximab administration to a pregnant woman. Rheumatology (Oxford) 2013;52:405–406.
    OpenUrlCrossRefPubMed
  48. 48.
    1. Ng CT,
    2. O'Neil M,
    3. Walsh D,
    4. Walsh T,
    5. Veale DJ
    . Successful pregnancy after rituximab in a women with recurrent in vitro fertilisation failures and anti-phospholipid antibody positive. Ir J Med Sci 2009;178:531–533.
    OpenUrlCrossRefPubMed
  49. 49.
    1. Ojeda-Uribe M,
    2. Gilliot C,
    3. Jung G,
    4. Drenou B,
    5. Brunot A
    . Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. J Perinatol 2006;26:252–255.
    OpenUrlCrossRefPubMed
  50. 50.
    1. Ojeda-Uribe M,
    2. Afif N,
    3. Dahan E, et al
    . Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheumatol 2013;32:695–700.
    OpenUrlCrossRefPubMed
  51. 51.
    1. Pellkofer H,
    2. Suessmair C,
    3. Schulze A,
    4. Hohlfeld R,
    5. Kuempfel T
    . Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab. Mult Scler 2009;15:1006–1008.
    OpenUrlCrossRefPubMed

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Glossary
    • Methods
    • Results
    • Discussion
    • Author contributions
    • Study funding
    • Disclosure
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Preferences and User Experiences of Wearable Devices in Epilepsy A Systematic Review and Mixed-Methods Synthesis

Dr. Daniel Friedman and Dr. Sharon Chiang

► Watch

Topics Discussed

  • Multiple sclerosis
  • Devic's syndrome

Alert Me

  • Alert me when eletters are published
Neurology - Neuroimmunology Neuroinflammation: 10 (2)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise